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Abstract
Background: Data on health-related quality of life (HRQoL) is paramount for shared and evidence based decision-
making. Since an overview of cervical cancer HRQoL tools and their validity appears to be lacking, we performed a
systematic review on usage of disease specific HRQoL instruments in cervical cancer patients and their psychometric
properties to identify the most suitable cervical cancer specific HRQoL tool.
Methods: We searched Pubmed, EMBASE and PsycINFO from inception up to 18 October 2016 for studies on quality of
life in cervical cancer patients. Data extraction and HRQoL identification was performed by two independent reviewers.
Validation studies of the identified cervical cancer specific HRQoL tools were retrieved and assessed on psychometric
properties using the COSMIN checklist. All used cervical cancer specific HRQoL instruments were scored and ranked
according to their psychometric properties.
Results: We included 156 studies (20,690 patients) and identified 31 HRQoL tools. The EORTC QLQ-CX24 (35 studies;
5,556 patients) and FACT-Cx (22 studies; 4,224 patients) were the only cervical cancer specific tools.
The EORTC QLQ-CX24 had 4 out of 9 positive rated psychometric properties; internal consistency, content and construct
validity, and agreement. Criterion validity, reliability, and interpretability scored doubtful. Responsiveness and floor- and
ceiling effects were not reported. The FACT-Cx had 2 out of 9 positive rated psychometric properties; internal consistency
and agreement. Content validity, reliability, and interpretability scored doubtful while criterion and construct validity
scored negative. Responsiveness and floor- and ceiling effects were not reported.
Conclusion: The validity of the often used EORTC QLQ-CX24 questionnaire for cervical cancer patients remains uncertain
as 5 out of 9 psychometric properties were doubtful or not reported in current literature. Cervical cancer specific HRQoL
tools should therefore always be used in conjunction with validated generic cancer HRQoL tools until proper validity has
been proven, or a more valid tool has been developed.
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Background
Treatment of the fourth most common cancer in
women, cervical cancer, consists of either surgery and/
or (chemo-)radiotherapy, based on the FIGO stage of
the disease [1, 2]. Depending on the treatment, different
side effects, such as: bladder, bowel, and vaginal dysfunc-
tion, lymphedema, and lymphocysts can occur [3, 4]. These
side effects, together with the emotional and social impact
of the disease, influence a patients’ health-related quality of
life (HRQoL), even when survival is extended. The accept-
ance of medical treatments is critically dependent on these
HRQoL consequences, making it one of the most import-
ant parameters in the evaluation of medical treatments.
Quality of life is a complex, multidimensional con-
struct, with a range of conceptual definitions and is
often evaluated using HRQoL tools. There is general
agreement that multidimensional HRQoL assessment
should at least include physical, social and psycho-
logical/emotional functioning and well-being [5]. The
validity and suitability of such HRQoL tools, is repre-
sented by their psychometric properties. Psychometric
properties indicate if a measurement tool is; free of error
(reliability), assesses what it is intended to measure (val-
idity), is able to detect change in an individual over time
(responsiveness), and the degree to which one can assign
qualitative meaning to quantitative scores (interpretabil-
ity) [6]. Using an instrument with (good) psychometric
properties that have been evaluated enables the user to
draw more robust and substantial conclusions. Since the
psychometric properties of a measurement tool can dif-
fer per target population, it is recommended that they
are evaluated in that specific target population.
Others have studied the psychometrics and appropriate-
ness of HRQoL tools in gynaecologic oncology in general
[7–9]. However, both a clear overview of the available dis-
ease specific HRQoL tools for cervical cancer patients and
an appraisal of their psychometric properties are lacking.
Vistad et al [10] reported on the impact of cervical cancer
on HRQoL, and critically appraised a number of studies
regarding HRQoL measurement in this population. How-
ever, they did not report or evaluate the psychometric
properties of the HRQoL instruments for cervical cancer.
Furthermore, FIGO stage is important in the treatment of
cervical cancer, and can result in different side effects in-
fluencing relevant aspects of HRQoL [2–4, 11]. As such,
the validity, reliability, and responsiveness of an HRQoL
tool can differ per disease stage. For a valid and patient-
centered evaluation of health status, it is important that
the HRQoL tool measures aspects of health status that are
important to patients with cervical cancer, and that the
measurement characteristics are adequate for the specific
patient population. Thus, we hypothesized that cervical
cancer-specific HRQoL tools will provide the most valid
and patient-centered evaluation of health status.
The aim of this study therefore is to provide an over-
view of the used HRQoL tools in cervical cancer pa-
tients, to identify cervical cancer specific HRQoL tools
and to assess their psychometric properties. This allows
for an evidence based choice of a cervical cancer specific
HRQoL tool in both clinical practice and clinical trials.
Methods
Data source and search
We systematically searched EMBASE, Pubmed, and Psy-
cINFO from inception up to 18 October 2016 for studies
on quality of life assessment in cervical cancer patients.
The search strategy combined synonyms for cervical
cancer, questionnaires and quality of life, see Additional
file 1 for the complete search strategy. All citations were
imported into the bibliographic database of EndNote X5
(Thomas Reuters, New York, NY, USA).
Study selection
After retrieving all the records in Endnote, duplicates
were removed and records were screened on title and
abstract for relevance by two independent reviewers
(M.E.S and C.T.). Inclusion criteria for full text assess-
ment were; (1) assessing quality of life in (2) patients
with cervical cancer using (3) an HRQoL tool [5], and
(4) availability of a full text (5) peer reviewed article. For
example, studies focusing on a single quality of life do-
main were excluded as the concept of HRQoL is multi-
dimensional. Whenever a full text questionnaire was not
available, the corresponding authors were contacted for
a copy in order to assess if the questionnaire did meet
the HRQoL definition. In case of disagreement, a third
reviewer was consulted (M.M.R.). All studies that were
included from the systematic review were documented
as supplemental references and contain the prefix ‘s’,
followed by the respective reference number.
Data extraction, synthesis and analysis
Two independent reviewers (M.E.S. and C.T.) extracted the
following data: HRQoL tool, number of cervical cancer pa-
tients, and their respective FIGO stage (Additional file 2).
An overview was made of all used HRQoL tools with the
number of included patients. A distinction was made be-
tween HRQoL tools for the following domains: generic
HRQoL, HRQoL for cancer in general, cervical cancer-
specific HRQoL, other cancer-specific HRQoL, and other
non-cancer but disease or symptom specific HRQoL tools.
Depending on the data presentation, we defined the follow-
ing stages as early stage cervical cancer; stage I, OR stage
IA, IB and IIA, OR stage IA1 + 2, IB1 and IIA1.
When two or more HRQoL tools were used in one
study, each HRQoL tool was included either in combin-
ation or as separate tool, based on their use. Thus, the
reported number of studies and/or patients can exceed
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the total overall included number of studies and/or pa-
tients from the systematic search. In case of disagree-
ment, a third reviewer was consulted (M.M.R).
Psychometric property assessment
As we hypothesized that cervical cancer-specific HRQoL
tools will provide the most valid and patient-centered
evaluation of health status, we only assessed psychometric
properties of the identified cervical cancer-specific HRQoL
tools. Psychometric property assessment of the cervical
cancer specific HRQoL tools was based on all available
studies in which one or more psychometric properties of
the tool were assessed and reported for cervical cancer pa-
tients. These studies were identified through the references
of studies that were already included after the first search
for HRQoL tools used in cervical cancer patients and by
searching the official website of the specific HRQoL tool.
Furthermore, we also searched Embase, Pubmed, and Psy-
cINFO using a search strategy that combined synonyms
and terms for cervical cancer, validation studies/psycho-
metrics and quality of life (Additional file 3). We also per-
formed a reference and related article search.
The psychometric properties were assessed according to
the COSMIN (COnsensus-based Standards for the selec-
tion of health Measurement Instruments) criteria pub-
lished by Terwee et al. [12] including content validity,
internal consistency, criterion validity, construct validity,
reproducibility (agreement, reliability), responsiveness,
floor- and ceiling effects, and interpretability. A scoring
model was used based on a positive (+), doubtful (?), or
negative (-) rating that was given to each psychometric
property [13]. If more than one validation study assessed
the same psychometric property, the best rating was used
as recommended by the COSMIN protocol. Unfortu-
nately, there are no methods available to pool results on
psychometric property testing from different validation
studies while taking their underlying methodological qual-
ity (weight) into account. We therefore reported all ratings
in order to provide a clear overview of the best rating and
the variation between validation studies for each psycho-
metric property. If no information was found on the psy-
chometrics, it was not assessable and was scored with an
“X”. See Additional file 4 for the definition of the psycho-
metric properties and their scoring criteria.
The ratings were not used for a total sum score per
HRQoL tool as each individual psychometric property can
have its own weight regarding the quality and the suitabil-
ity of the cervical cancer specific HRQoL tools [12].
Results
Figure 1 provides an overview of the literature search
and study selection. Our literature search yielded 2184
unique records, of which 320 remained after screening
titles and abstracts. The full-text of these studies was
reviewed for eligibility. Studies were excluded for the fol-
lowing reasons: not including an HRQoL assessment (89),
duplicates (23), non-cervical cancer patients (21), valid-
ation study (13), review (12), a cost-effectiveness study (4),
and no full text copy of the questionnaire available (2).
This yielded 156 studies (20,690 patients) using 31 differ-
ent HRQoL tools. See Additional file 5 with the supple-
mental references for a list of all included studies and
their respective reference number, with the prefix ‘s’.
HRQoL tools, type and frequency
The 31 identified HRQoL tools were categorized as gen-
eric (n = 10), cancer-specific (n = 9), and cervical cancer-
specific-tools (n = 2). Other disease specific HRQoL tools
that were used in cervical cancer patients were related
to ovarian (n = 1), bladder (n = 1), breast (n = 1), or brain
cancer (n = 1), or to chronic illness (n = 2), terminal care
(n = 1), rectal bleeding (n = 1), fecal incontinence (n = 1),
or menopause (n = 1). Table 1 provides an overview of
the identified tools, their abbreviations, their frequency,
and number of patients assessed with that tool.
The two cervical cancer specific HRQoL tools used
were the EORTC QLQ-CX24 and FACT-Cx, which were
used in 35 and 22 studies including 5,556 and 4,224 pa-
tients, respectively. In 3 studies (n = 574 patients) the
EORTC QLQ-CX24 was combined with another, mostly
a more generic HRQoL tool (Table 2). The FACT-Cx
was combined with another HRQoL tool in 8 studies (n
= 1,915 patients). The EORTC QLQ-CX24 was used in
68% early FIGO stage cervical cancer patients as com-
pared to 29% with the FACT-Cx,
Psychometric properties
Table 3 shows the psychometric properties of the
EORTC QLQ-CX24 and FACT-Cx. For the EORTC
QLQ-CX24 and FACT-Cx, 7 and 3 validation studies
were available with study populations ranging from 100
to 860 patients.
EORTC QLQ-CX24
There is positive evidence regarding the content validity,
construct validity, internal consistency, and agreement
since the items in the questionnaire were extensively se-
lected involving both patients and investigators; the
scores of the tool were related to the treatment status as
hypothesized prior to the study; Cronbach’s α was above
0.70; and the test-retest showed an ICC between 0.85
and 0.89, respectively. The criterion validity and reliability
are uncertain as a questionable reference standard was
used to validate the tool’s score to a reference standard
and/or inappropriate statistical methods were used. These
methods included: calculating a Cohen’s D, Kruskall Wallis,
Mann-Whitney, Wilcoxon, students’ t-test, or ANOVA
with a p-value between the subgroups to prove that
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patients could be distinguished from each other in sub-
groups, such as early and advanced FIGO stage or treat-
ment status, based on the tool’s score. The interpretability
of the EORTC QLQ-CX24 score is limited as a minimal
important change was not defined. Responsiveness and
floor- and ceiling effects were also not assessed in any of
the validation studies. The scoring model resulted in 4
positive, 3 doubtful, and 2 not assessable psychometrics for
the EORTC QLQ-CX24, out of a maximum of 9.
FACT-Cx
There is positive evidence regarding the internal
consistency and agreement as items per (sub)scale were
correlated with a Cronbach’s α above 0.70 and the test-
retest showed an ICC between 0.68 and 0.84. However,
there is no evidence available regarding the content val-
idity, i.e. it is unclear how the questionnaire was built
and how the specific questions were selected. The reliabil-
ity of the FACT-Cx is uncertain as again, inappropriate
statistical methods were used to prove that patients could
be distinguished from each other in subgroups such as
early and advanced FIGO stage or treatment status, based
on the tool’s score. The interpretability of the FACT-Cx
score is limited as a minimal important change was not
defined. Responsiveness and floor- and ceiling effects were
also not assessed in any of the validation studies. The cri-
terion and construct validity were limited as the correl-
ation α with the studied reference standard (SF-36) was
below 0.70 and less than 75% of the hypotheses on how
the scores of the questionnaire would relate to other mea-
sures in a manner that was consistent with theoretically
derived hypotheses were confirmed.
The scoring model resulted in 2 positive, 3 doubtful, 2
not assessable, and 2 negative psychometrics for the
FACT-Cx, out of a maximum of 9.
All validation studies included early and advanced
stage cervical cancer patients and patients in these sub-
groups could be distinguished, based on their overall
Fig. 1 Flow diagram of the study selection
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Table 1 HRQoL tools, number of times used in literature, full name and identified validation studies
Studies Early
stage
Advanced
stage
Overall Full name
General
SF-36 21 1025 436 3452 36-Item Short Form health survey [s1–s21]
WHOQOL-
BREF
9 415 281 963 WHO Quality of Life – Abbreviated [s22–s30]
SF-12 8 569 443 1263 12-Item Short Form health survey [s31–s38]
EQ-5D 7 655 363 2287 Euroqol-5D [s21, s39–s44]
VR 12 1 0 0 1016 Veterans Rand 12-Item Health Survey [s20]
SF8 1 311 218 529 8-Item Short Form health survey [s43]
PROMIS 4 294 108 565 Patient Reported Outcomes Measurement Information System [s45–s48]
QL-I 1 34 45 79 Quality of Life Index [s49]
PGWB 1 24 22 46 Psychological General Well-Being [s50]
ALLTAG 1 24 22 46 [German] Questionnaire on everyday life [s50]
Total 54 3351 1938 10246
Cancer
FACT-G 26 634 2126 3807 Functional Assessment of Cancer Therapy – General [s15, s33, s51–s74]
EORTC QLQ-
C30
29 344 561 2792 European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire,
Core module [s13, s14, s49, s75–s97]
FACT NTX 3 0 1108 1108 Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity
[s69, s70, s72]
FACT-GP 2 147 54 221 Functional Assessment of Cancer Therapy - General Population [s47, s48]
QOL-CS 2 0 0 72 Quality of Life – Cancer Survivors [s17, s100]
CARES-SF 1 0 0 129 Cancer Rehabilitation Evaluation System – Short Form [s93]
FACT AN 1 0 115 115 Functional Assessment of Cancer Therapy-Anemia [s73]
SDCQ 1 0 0 59 Socio-demographic and Clinical Questionnaire [s101]
MQOLS-CA 1 0 0 38 Multidimensional Quality of Life. Scaled Cancer [s102]
Total 66 1125 3964 8341
Cx specific
EORTC QLQ-
CX24
35 3212 1508 5556 European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire,
Cervical cancer module [s18, s21, s103–s135]
FACT-Cx 22 1231 2973 4224 Functional Assessment of Cancer Therapy – Cervical cancer [s32, s38, s46–s48 s69–s72,
s136–s148]
Total 57 4443 4481 9780
Other cancer specific
Ovarium specific
ORTC
QLQ-
OV28
1 0 0 27 European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire,
Ovarian cancer module [s96]
Bladder Cancer
FACT BL 1 0 0 13 Functional Assessment of Cancer Therapy – Bladder cancer [s149]
Breast Cancer
FACT-B 1 0 0 10 Functional Assessment of Cancer Therapy – Breast cancer [s150]
Brain Cancer
FACT-BR 1 0 1 1 Functional Assessment of Cancer Therapy – Brain cancer [s151]
Total 4 0 1 51
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scores. However, the psychometric properties per sub-
group were not reported and thus not assessable for nei-
ther the EORCT QLQ-CX24 nor the FACT-Cx.
Discussion
The FACT-Cx and EORTC QLQ-CX24 were the identi-
fied cervical cancer-specific HRQoL tools, which were
used in 22 and 35 out of 156 studies, respectively. The
EORTC QLQ-CX24 appears to be the most used and a
more appropriate tool to assess HRQoL in cervical can-
cer patients. However, its validity is uncertain since 5
out of 9 psychometric properties are doubtful or not re-
ported in current literature. For example, no correlation
was found between the performance of the tool and a
reference standard, the minimal important change that
should be detected was not defined, and floor and
ceiling effects were not reported. The validity of the
FACT- Cx is even more uncertain as 7 out of the 9 psy-
chometric properties were doubtful or not reported at
all. Similar problems as with the EORTC were reported;
there was no correlation found between the performance
of the tool and a reference standard, the minimal im-
portant change that should be detected was not defined,
and floor and ceiling effects were not reported. But for
the FACT-Cx there was also no description on how the
questionnaire and its items were selected, hypotheses re-
garding the scores were not confirmed, and it remained
unclear if repeated measurements over a longer period
of time can detect a (relevant) change in quality of life.
Thus the EORTC QLQ-CX24 has been more thor-
oughly assessed regarding its psychometric properties and
scored better (both regarding the number of positively
rated psychometric properties and the score per psycho-
metric property) when compared to the FACT-Cx.
To our knowledge, this is the first systematic review that
identified different HRQoL tools that have been used to
assess quality of life in patients with cervical cancer. We
used the COSMIN checklist for a thorough evaluation of
the quality of the two cervical cancer specific HRQoL
tools. We have provided evidence that the EORTC QLQ-
CX24 is the most appropriate and valid cervical cancer-
specific HRQoL for a patient-centered evaluation of health
status of cervical cancer patients in general.
Our study has a few limitations. First, one possible
HRQoL tool, the SES-QOL, could not be included as
there was no full text copy of the tool available. Despite
repeated requests, we did not receive a full text copy
Table 1 HRQoL tools, number of times used in literature, full name and identified validation studies (Continued)
Other
Terminal care
MVQOLI 1 0 32 32 Missoula-VITAS Quality of Life Index [s152]
Menopause
WHQ 30 1 0 0 15 Woman’s Health Questionnaire [s153]
Chronic illness
FACT-SP 2 19 91 114 Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being [s133, s154]
FACT F 1 0 1 1 Functional Assessment of Chronic Illness Therapy-Fatigue [s97]
Rectal bleeding
RBQOLS 1 0 0 2 Rectal Bleeding Quality of Life Scale [s155]
Fecal incontinence
FIQLI 1 0 0 21 Fecal Incontinence Quality of Life [s156]
Total 7 19 124 185
Total Overall a 156 6848 7053 20690
a Total numbers differ as a study and/or study population can be counted more than once in and between categories while only counting once for the overall
total
Table 2 Cervical cancer specific HRQoL tool usage
Studies Early stage Advanced stage Overall
As single tool
EORTC QLQ-CX24 32 2836 1350 4982
FACT-Cx 14 706 1603 2309
EORTC QLQ-Cx24 in combination with a
EQ-5D & SF-36 1 247 39 291
SF-36 1 110 28 173
FACT Sp 1 19 91 110
FACT-Cx in combination with b
NTX 3 0 1108 1108
PROMIS 3 294 108 422
SF-12 2 231 154 385
a The QLQ-C30 core questionnaire did not count as a combination
b The FACT-G core questionnaire did not count as a combination
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and had to exclude this tool from our results as we
could not assess whether it meets the HRQoL definition.
On the other hand, as the SES-QOL is not a cervical
cancer specific HRQoL tool it would not have influenced
our final conclusion.
Second, almost all psychometric properties highly
depend on methods and design of the validation
study. For instance, a property such as construct val-
idity could score positively if only one hypothesis was
tested and confirmed (>75% confirmed), while rated
negatively when another hypotheses was tested but
rejected (<75% confirmed). Thus the rating of an
HRQoL tools’ validity could therefore also be a repre-
sentation of the validation study design, instead of the
actual validity. Regardless, the uncertainty surround-
ing the validity of cervical cancer-specific HRQoL
tools remains, and more evidence is needed to reduce
this uncertainty.
Do note that the scoring model that we applied cannot
be used to calculate an ‘overall’ score as the weight of each
individual psychometric property can differ per specific
design, application and/or study population, e.g. construct
validity, reliability for discriminating between different
(sub)groups, and responsiveness for the evaluation of
treatment effects [12]. Thus, an external comparison on
validity across HRQoL tools is only possible per psycho-
metric property and not on an ‘overall’ score.
Third, the psychometric properties in the identified
studies were often not reported, incorrect or unclear, and
the terminology and definitions differed from those pro-
posed by Terwee et al [12]. Regardless, this is the most
up-to-date overview of current available literature and it
should be noted that the absence of evidence on the above
mentioned psychometric properties, either due to no re-
ported data or inappropriate design/methods, is not to be
confused with evidence of their absence.
Table 3 Psychometric properties of the cervical cancer-specific HRQoL tools
FACT-CX Overall
Study Ding [21] Fernandes [22] Fregnani [23]
Country China Brazil Brazil
Number of participants 400 149 100
Content validity ? X ? ?
Internal consistency + + + +
Criterion validity ? X - -
Construct validity - X - -
Agreement X X + +
Reliability ? X ? ?
Responsiveness X X X X
Floor- & ceiling effects X X X X
Interpretability ? X ? ?
EORTC QLQ-CX24 Overall
Study Greimel [14] Jayaskera [17] Singer [19] Hua [16] Shin [18] Du Toit [15] Paradowska [20]
Country multiple Sri Lanka Germany China Korea South Africa Poland
Number of participants 167 112 134 115 860 208 171
Content validity + ? ? ? X ? ? +
Internal consistency + + + + + + + +
Criterion validity ? X ? ? ? ? ? ?
Construct validity X + X X X X X +
Agreement X X X X X X + +
Reliability ? ? ? ? ? ? ? ?
Responsiveness X X X X X X X X
Floor- & ceiling effects X X X X X X X X
Interpretability ? ? ? ? ? ? ? ?
?; doubtful design/methods thus no quantitative or qualitative scoring possible
X; not reported therefore no quantitative or qualitative scoring possible
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Based on our results, the use of only a cervical
cancer-specific HRQoL tool is not preferred since its
validity remains to be proven. We therefore recom-
mend to always use a well-validated generic HRQoL
tool to be able to ascertain the most valid and
patient-centered evaluation of health status, both in
clinical practice and clinical trials. In addition, by
using already well-validated generic HRQoL tools in
combination with one of the cervical cancer-specific
tools, researchers will be able to properly assess the
psychometric properties of the FACT-Cx and EORTC
QLQ-CX24. Another option could be to develop a
new and more valid HRQoL tool. However, this may
be redundant as there remains uncertainty regarding
the validity of already available HRQoL tools and the
absence of evidence on their validity should not to be
confused with evidence of absent valid tools. For both
the validation of current HRQoL tools and develop-
ment of a new tool, we would recommend to use an
established protocol, such as the quality criteria pre-
sented by Terwee et al [12]. A data presentation with
an assessment of psychometric properties for both
early and advanced stage cervical cancer is warranted
as their treatment and subsequent possible side ef-
fects differ distinctively [14–21].
Conclusion
The validity of the often used EORTC QLQ-CX24 ques-
tionnaire for cervical cancer patients remains uncertain
since 5 out of 9 psychometric properties were doubtful
or not reported in current literature. Cervical cancer
specific HRQoL tools should therefore always be used in
conjunction with validated generic cancer HRQoL tools
until proper validity has been proven, or a more valid
tool has been developed.
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